Highlight
1. Spatial proteomics reveals complex heterogeneity within and around granulomas in cardiac sarcoidosis (CS).
2. Even tissue regions without visible inflammation exhibit distinct immune and metabolic protein signatures characterizing CS.
3. A seven-protein biomarker panel accurately distinguishes inflammation-free CS tissue from controls, potentially improving biopsy diagnostics.
4. This study opens new avenues for understanding CS pathogenesis using archival human cardiac tissue, overcoming current model limitations.
Study Background: Disease Burden and Diagnostic Challenges of Cardiac Sarcoidosis
Cardiac sarcoidosis (CS) is a potentially life-threatening manifestation of sarcoidosis characterized by granulomatous inflammation in the heart. CS can lead to arrhythmias, heart failure, and sudden cardiac death, posing a significant clinical challenge. Diagnosis is notoriously difficult due to heterogeneous presentation and the paucity of sensitive, specific biomarkers. Imaging and clinical criteria often lack diagnostic precision, and endomyocardial biopsy—despite its potential for definitive diagnosis—is limited by sampling error and nonspecific histopathology. Furthermore, the absence of reliable animal models restricts mechanistic understanding and therapeutic development for CS. Thus, innovative approaches that can interrogate human cardiac tissue at high resolution are urgently needed.
Study Design: High-Plex Spatial Protein Profiling of Cardiac Tissue
This study leveraged the GeoMx Digital Spatial Profiler to perform high-plex, spatially resolved protein analysis on cardiac tissue specimens from 64 patients, including 39 with clinically and histologically confirmed CS and 25 controls without CS. Formalin-fixed, paraffin-embedded cardiac tissue samples were analyzed, focusing on regions of interest (ROIs) both with granulomatous inflammation and without visible inflammation. The ROIs were further partitioned into microanatomic compartments—cardiomyocytes, stromal cells, and vascular structures—to capture spatially segregated protein profiles. A curated panel of 79 proteins that encompass immune markers, fibrotic components, and metabolic enzymes was used. The study employed mixed-effects modeling to assess differential protein abundance while accounting for intra- and inter-patient variability. A predictive model was subsequently developed based on a subset of seven proteins to discriminate inflammation-free CS ROIs from control ROIs.
Key Findings
1. Heterogeneity Within Granulomatous Inflammation
Spatial protein profiling revealed marked heterogeneity both within individual granulomas and across patient samples. This underscores the complex immunopathology of CS, reflecting varied cellular composition and functional states even in close proximity within granulomas. Such heterogeneity may contribute to variable clinical phenotypes and response to therapy.
2. Distinct Immune and Metabolic Signature in Inflammation-Free Tissue
Surprisingly, regions of cardiac tissue from CS patients lacking overt granulomatous inflammation also demonstrated a distinctive “distance gradient” in protein expression. Protein abundance varied systematically according to proximity to granulomatous foci, indicating that the CS microenvironment extends beyond visible lesions. This includes altered immune signaling molecules, extracellular matrix proteins, and metabolic markers, suggesting that subclinical activities may contribute to disease progression or maintenance.
3. Predictive Protein Panel for Diagnostic Purposes
The study developed a robust seven-protein classifier that differentiated inflammation-free CS ROIs from control ROIs with an accuracy of 95.9% and an area under the receiver operating characteristic curve (AUC) of 0.993. This near-perfect performance is remarkable given the absence of visible inflammation in these tissue regions. If validated prospectively, such a protein panel could significantly enhance the diagnostic yield of cardiac biopsies in suspected CS.
4. Insights Into Pathogenesis and Potential Therapeutic Targets
The ability to spatially resolve immune milieu and metabolic changes around granulomas provides fresh perspectives on CS pathogenesis. Identifying protein pathways active in ostensibly normal tissue might reveal early disease mechanisms and potential targets for intervention before the development of irreversible fibrosis or arrhythmogenic remodeling.
Expert Commentary
This study represents a landmark in CS research by applying cutting-edge spatial proteomics to archived human cardiac tissue. Not only does it overcome the limitations imposed by the lack of suitable animal models but it also addresses the central diagnostic dilemma: how to identify disease in elusive tissue compartments. The discovery of an immune signature in areas lacking granulomas challenges the traditional notion that only granulomatous inflammation is pathognomonic of CS, suggesting a continuum of disease activity.
Nonetheless, the study has limitations. The retrospective design and use of archival samples may introduce biases related to tissue preservation. The cohort size, while substantial for a rare disease, warrants validation in larger, prospective cohorts. Additionally, clinical correlation with imaging and electrocardiographic findings would help translate proteomic discoveries into clinical algorithms.
Future research might explore how these protein profiles evolve longitudinally with therapy or disease progression, potentially guiding personalized medicine strategies.
Conclusion
This pioneering spatial proteomic analysis uncovers previously unrecognized heterogeneity in cardiac sarcoidosis, extending beyond granulomatous lesions to reveal a distinct immune and metabolic milieu in ostensibly uninvolved tissue. The identification of a highly accurate seven-protein biomarker panel holds promise to enhance diagnostic precision in clinical biopsies, a critical unmet need in CS management. Overall, these findings not only advance mechanistic understanding of CS but also provide a platform for improved clinical diagnostics and potentially targeted therapies.
Funding and Clinical Trials
The original study was supported by [funding details as per source]. No specific clinical trial registration information was noted.
References
1. Peyster EG, Smith D, Bittermann T, Bravo PE, Margulies KB. Cardiac sarcoidosis: new insights beyond the granuloma using spatial proteomics. Eur Heart J. 2026 Jun 23;47(24):3174-3188. PMID: 41431931.
2. Cooper LT Jr. Sarcoidosis of the heart: diagnosis, prognosis, and therapy. Heart Fail Rev. 2009;14(3):259-264.
3. Birnie DH, Nery PB, Ha A, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68(4):411-421.
4. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361(9363):1111-1118.
